Mission Bio and German Research Consortium Identify Single-Cell Biomarker Signal That May Predict Motixafortide Benefit in AML Mission Bio, a leader in single-cell multiomics, has jointly announced new findings with Heidelberg University Hospital, Martin Luther University Halle-Wittenberg, the East German…
Moonlight Therapeutics Launches First-in-Human Phase I Trial of MOON101 for Peanut Allergy Moonlight Therapeutics, Inc., a clinical-stage biotechnology company focused on developing innovative treatments for food allergies, has announced the initiation of its first-in-human Phase I clinical trial evaluating MOON101,…
Camizestrant Combination Reduced Risk of First and Second Disease Progression in ESR1-Mutant Advanced HR-Positive Breast Cancer in SERENA-6 AstraZeneca has announced updated positive findings from its pivotal Phase III SERENA-6 clinical trial, reinforcing the potential of camizestrant in combination with…
Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in combination with…
Corsair Pharma Reports Successful Phase 1 Results for TRX-248 Transdermal System in Pulmonary Arterial Hypertension Corsair Pharma, Inc., a private biopharmaceutical company focused on innovative drug delivery technologies, has announced positive results from its first-in-human Phase 1 clinical trial evaluating…
Qurient Doses First Patient in Phase 2 Trial of Mocaciclib for CDK4/6 Inhibitor-Resistant HR-Positive Breast Cancer Qurient Co., Ltd. has announced a major clinical development milestone with the dosing of the first patient in a Phase 2 study evaluating mocaciclib…
Sumitomo Pharma America Reports Promising Early Clinical Results for Investigational CHK1 Inhibitor SMP-3124LP in Advanced Solid Tumors Sumitomo Pharma America, Inc. (SMPA) has unveiled encouraging clinical findings from its ongoing first-in-human Phase 1/2 study evaluating SMP-3124LP, an investigational checkpoint kinase…
Virion Therapeutics Reports Durable Functional Cure Signals in Chronic Hepatitis B with Single-Dose VRON-0200 at EASL 2026 Virion Therapeutics, LLC, a clinical-stage biotechnology company focused on developing next-generation T cell–based immunotherapies for chronic viral diseases, has announced compelling long-term clinical…
Bristol Myers Squibb’s Mezigdomide Combo Shows Strong Phase 3 Success in Relapsed Multiple Myeloma at ASCO 2026 Bristol Myers Squibb has announced encouraging late-breaking results from the Phase 3 SUCCESSOR-2 clinical trial evaluating its investigational CELMoD therapy mezigdomide in combination…
BeOne Medicines Showcases Long-Term BRUKINSA Success and Next-Generation CLL Treatment Advances at ASCO 2026 BeOne Medicines Ltd., a global oncology company dedicated to developing innovative cancer therapies, is presenting extensive new data at the 2026 American Society of Clinical Oncology…
Otsuka Pharmaceutical Development & Commercialization Presents New Phase 3 Centanafadine Analyses Highlighting Broader ADHD Symptom Improvements Otsuka Pharmaceutical Co., Ltd. and Otsuka Pharmaceutical Development & Commercialization unveiled new post hoc exploratory analyses from two pivotal Phase 3 clinical studies evaluating…
PharmaEssentia Names Eric Vogel as U.S. Commercialization Head in Preparation for Potential BESREMi® Launch in Essential Thrombocythemia PharmaEssentia Corporation has announced the appointment of Eric Vogel as the company’s new U.S. Head of Commercialization, strengthening its leadership team as it…